Platinum International Biotech Co., Ltd acquired Yubo International Biotech Limited for approximately $380 million in a reverse merger transaction.
The closing transaction is subject to conditions precedent, including, Platinum and Yubo shall have received approvals, authorizations, qualifications and orders of governmental authorities and other third parties, Yubo shall have received from Platinum, the audited financial statements and proforma financial statements, Yubo shareholders shall have adopted and approved this agreement, terminations or expirations of waiting periods imposed by, any Governmental Entity shall have been obtained and others. The share exchange has been approved by the Board of Directors of both Platinum International Biotech Co. and Yubo International Biotech Limited. Mark C. Lee of Greenberg Traurig, LLP acted as legal advisor to Yubo International Biotech.
Platinum International Biotech Co., Ltd completed the acquisition of Yubo International Biotech Limited (OTCPK:YBGJ) in a reverse merger transaction on January 14, 2021.